Overcoming barriers to oncology combination therapies in the UK and EU
Colleagues at IQVIA discuss ways to expedite positive HTA outcomes for innovative combination therapies, alleviating the bottlenecks inherent in the current system.
List view / Grid view
Colleagues at IQVIA discuss ways to expedite positive HTA outcomes for innovative combination therapies, alleviating the bottlenecks inherent in the current system.
Discover how interactive response technology (IRT) is revolutionising the management of cell and gene therapy (CGT) trials by streamlining complex workflows, ensuring regulatory compliance and enhancing patient outcomes.
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
Proactive approaches to labelling and artwork in preclinical stages of drug development reduce delays, minimise risk and expedite time to market.